Effect of carbamazepine and oxcarbazepine on wild-type and mutant neuronal nicotinic acetylcholine receptors linked to nocturnal frontal lobe epilepsy

European Journal of Pharmacology

Volumn 643, Issue 1, 2010, Pages 13-20

  Di Resta, Chiara ^a   Ambrosi, Paola ^a   Curia, Giulia ^a   Becchetti, Andrea ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

ADNFLE; GP 47779; I279N; MHD; 2 4; 4 2

Indexed keywords

CARBAMAZEPINE; LICARBAZEPINE; MUTANT PROTEIN; NICOTINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA2BETA4; NICOTINIC RECEPTOR ALPHA4BETA2; OXCARBAZEPINE; UNCLASSIFIED DRUG;

ANTICONVULSANT ACTIVITY; ARTICLE; CELL STRAIN HEK293; CHOLINERGIC SYSTEM; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG STRUCTURE; FRONTAL LOBE EPILEPSY; HUMAN; HUMAN CELL; IC 50; PATCH CLAMP; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; WILD TYPE;

EID: 77955086763     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.05.063     Document Type: Article

References (58)

1. Albuquerque E.X., Pereira E.F.R., Alkondon M., Rogers S.W. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol. Rev. 2009, 89:73-120.
2. Ambrósio A.F., Soares-da-Silva P., Carvalho C.M., Carvalho A.P. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem. Res. 2002, 27:121-130.
3. Aracri P., Consonni S., Morini R., Perrella M., Rodighiero S., Amadeo A., Becchetti A. Tonic modulation of GABA release by nicotinic acetylcholine receptors, in layer V of the murine prefrontal cortex. Cereb. Cortex 2010, 20(7):1539-1555.
4. Aridon P., Marini C., Di Resta C., Brilli E., De Fusco M., Politi F., Parrini E., Manfredi I., Pisano T., Pruna D., Curia G., Cianchetti C., Pasqualetti M., Becchetti A., Guerrini R., Casari G. Increased sensitivity of the neuronal nicotinic receptor α2 subunit causes familial epilpsy with nocturnal wandering and ictal fear. Am. J. Hum. Genet. 2006, 79:342-350.
5. Benes J., Parada A., Figueiredo A.A., Alves P.C., Freitas A.P., Learmonth D.A., Cunha R.A., Garrett J., Soares-da-Silva P. Anticonvulsant and sodium channel-blocking properties of novel 10, 11-dihydro-5H-dibenz[b, f]azepine-5-carboxamide derivatives. J. Med. Chem. 1999, 42:2582-2587.
6. Bertrand D., Picard F., Le Hellard S., Weiland S., Favre I., Phillips H., Bertrand S., Berkovic S.F., Malafosse A., Mulley J. How mutations in the nAChRs can cause ADNFLE epilepsy. Epilepsia 2002, 43:112-122.
7. Beydoun A., Nasreddine W.M., Albini F. Oxcarbazepine. Epilepsy. A Comprehensive Textbook 2008, 1593-1598. Lippincott Williams and Wilkins, Philadelphia, PA. second ed. J. Engel, T.A. Pedley (Eds.).
8. Buisson B., Bertrand D. Chronic exposure to nicotine upregulates the human α47beta;2 nicotinic acetylcholine receptor function. J. Neurosci. 2001, 21:1819-1829.
9. Chavez-Noriega L.E., Crona J.H., Washburn M.S., Urrutia A., Elliott K.J., Johnson E.C. Pharmacological characterization of recombinant human neuronal nicotinic ecetylcholine receptors hα2β2, hα2β4, hα3β2, hα3β4, hα4β2, hα4β4 and hα7 expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 1997, 280:346-356.
10. Couey J.J., Meredith R.M., Spijker S., Poorthuis R.B., Smit A.B., Brussaard A.B., Mansvelder H.D. Distributed network actions by nicotine increase the threshold for spike-timing-dependent plasticity in prefrontal cortex. Neuron 2007, 54:73-87.
11. Dam M., Ekberg R., Loyming Y., Waltimo O., Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res. 1989, 3:70-76.
12. De Fusco M., Becchetti A., Patrignani A., Annesi G., Gambardella A., Quattrone A., Ballabio A., Wanke E., Casari G. The nicotinic receptor α2 subunit is mutant in nocturnal frontal lobe epilepsy. Nat. Genet. 2000, 26:275-276.
13. Gahring L.C., Persiyanov K., Rogers S.W. Neuronal and astrocyte expression of nicotinic receptor subunit beta4 in the adult mouse brain. J. Comp. Neurol. 2004, 468:322-333.
14. Giustizieri M., Armogida M., Berretta N., Federici M., Piccirilli S., Mercuri N.B., Nistico R. Differential effect of carbamazepine and oxcarbazepine on excitatory synaptic transmission in rat hippocampus. Synapse 2008, 62:783-789.
15. Gotti C., Moretti M., Bohr I., Ziabreva I., Vailati S., Longhi R., Riganti L., Gaimarri A., McKeith I.G., Perry R.H., Aarsland D., Larsen J.P., Sher E., Beattie R., Clementi F., Court J.A. Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation. Neurobiol. Dis. 2006, 23:481-489.
16. Gotti C., Clementi F., Fornari A., Gaimarri A., Guiducci S., Manfredi I., Moretti M., Pedrazzi P., Pucci L., Zoli M. Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem. Pharmacol. 2009, 78:703-711.
17. Han Z.Y., Le Novere N., Zoli M., Hill J.A., Champtiaux N., Changeux J.P. Localization of nAChR subunit mRNAs in the brain of Macaca mulatta. Eur. J. Neurosci. 2000, 12:3664-3674.
18. Hellström-Lindahl E., Gorbounova O., Seiger A., Mousavi M., Nordberg A. Regional distribution of nicotinic receptors during prenatal development of human brain and spinal cord. Brain Res. Dev. Brain Res. 1998, 108:147-160.
19. Hoda J.-C., Manischeck M., Bertrand D., Steinlein O.K. Pleiotropic functional effects of the first epilepsy-associated mutation in the human CHRNA2 gene. FEBS Lett. 2009, 583:1599-1604.
20. Ishii K., Wong J.K., Sumikawa K. Comparison of α2 nicotinic acetylcholine receptor subunit mRNA expression in the central nervous system of rats and mice. J. Comp. Neurol. 2005, 493:241-260.
21. Johannessen S.I., Battino D., Berry D.J., Bialer M., Krämer G., Tomson T., Patsalos P.N. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther. Drug Monit. 2003, 25:347-363.
22. Kedmi M., Beaudet A.L., Orr-Urtreger A. Mice lacking neuronal nicotinic acetylcholine receptor β4-subunit and mice lacking both α5- and β4-subunits are highly resistant to nicotine-induced seizures. Physiol. Genomics 2004, 17:221-229.
23. Kim J. Association of CHRNA2 polymorphisms with overweight/obesity and clinical characteristics in a Korean population. Clin. Chem. Lab. Med. 2008, 46:1085-1089.
24. Kulak J.M., Fan H., Schneider J.S. β2* and β4*nicotinic acetylcholine receptor expression changes with progressive parkinsonism in non-human primates. Neurobiol. Dis. 2007, 27:312-319.
25. Lambe E.K., Picciotto M.R., Aghajanian G.K. Nicotine induces glutamate release from thalamocortical terminals in prefrontal cortex. Neuropsychopharmacology 2003, 28:216-225.
26. Lendvai B., Vizi E.S. Nonsynaptic chemical transmission through nicotinic acetylcholine receptors. Physiol. Rev. 2008, 88:333-340.
27. Leniger T., Kananura C., Hufnagel A., Bertrand S., Bertrand D., Steinlein O.K. A new Chrna4 mutation with low penetrance in nocturnal frontal lobe epilepsy. Epilepsia 2003, 44:981-985.
28. Lloyd P., Flesch G., Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 1994, 35:S10-S13.
29. Luetje C.W., Patrick J. Both α- and β-subunits contribute to the agonist sensitivity of neuronal nicotinic acetylcholine receptors. J. Neurosci. 1991, 11:837-845.
30. McLean M.J., MacDonald R.L. Carbamazepine and 10-11 epoxicarbamazepine produce use- and voltage-dependent limitation of rapidly firing action potentials of mouse central neurons in cell culture. J. Pharmacol. Exp. Ther. 1986, 238:727-738.
31. MacDonald R.L., Rogawski M.A. Cellular effects of antiepileptic drugs. Epilepsy. A Comprehensive Textbook 2008, 1433-1445. Lippincott Williams and Wilkins, Philadelphia, PA. second ed. J. Engel, T.A. Pedley (Eds.).
32. Nakauchi S., Brennan R.J., Boulter J., Sumikawa K. Nicotine gates long-term potentiation in the hippocampal CA1 region via the activation of alpha2*nicotinic ACh receptors. Eur. J. Neurosci. 2007, 25:2666-2681.
33. Oldani A., Zucconi M., Asselta R., Modugno M., Bonati M.T. Autosomal dominant nocturnal frontal lobe epilepsy. A video-polysomnographic and genetic appraisal of 40 patients and delineation of the epileptic syndrome. Brain 1998, 121:205-223.
34. Oldfield S., Hancock J., Mason A., Hobson S.A., Wynick D., Kelly E., Randall A.D., Marrion N.D. Receptor-mediated suppression of potassium currents requires colocalization within lipid rafts. Mol. Pharmacol. 2009, 76:1279-1289.
35. Ortells M.O., Barrantes G.E. Molecular modelling of the interactions of carbamazepine and a nicotinic receptor involved in the autosomal dominant nocturnal frontal lobe epilepsy. Br. J. Pharmacol. 2002, 136:883-895.
36. Phillips H.A., Favre I., Kirkpatrick M., Zuberi S.M., Goudie D., Heron S.E., Scheffer I.E., Sutherland G.R., Berkovic S.F., Bertrand D., Mulley J.C. CHRNB2 is the second acetylcholine receptor subunit associated with autosomal dominant nocturnal frontal lobe epilepsy. Am. J. Hum. Genet. 2001, 68:225-231.
37. Picard F., Bertrand S., Steinlein O.K., Bertrand D. Mutated nicotinic receptors responsible for autosomal dominant nocturnal frontal lobe epilepsy are more sensitive to carbamazepine. Epilepsia 1999, 40:1198-1209.
38. Picard F., Brodtkorb E. Familial frontal lobe epilepsies. Epilepsy. A Comprehensive Textbook 2008, 2495-2502. Lippincott Williams and Wilkins, Philadelphia, PA. second ed. J. Engel, T.A. Pedley (Eds.).
39. Provini F., Plazzi G., Montagna P., Lugaresi E. The wide clinical spectrum of nocturnal frontal lobe epilepsy. Sleep Med. Rev. 2000, 4:375-386.
40. Quik M., Polonskaya Y., Gillespie A., Jakowec M., Lloyd K.G., Langston W.J. Localization of nicotinic receptor subunit mRNAs in monkey brain by in situ hybridization. J. Comp. Neurol. 2000, 425:58-69.
41. Raju G.P., Sarco D.S., Poduri A., Riviello J.J., Bergin A.M.R., Takeoka M. Oxcarbazepine in children with nocturnal frontal-lobe epilepsy. Pediatr. Neurol. 2007, 37:345-349.
42. Romigi A., Marciani M.G., Placidi F., Pisani L.R., Izzi F., Torelli F., Prosperetti M.D. Oxcarbazepine in nocturnal frontal-lobe epilepsy: a further interesting report. Pediatr. Neurol. 2008, 39:298.
43. Salas R., Cook K.D., Bassetto L., De Biasi M. The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice. Neuropharmacology 2004, 47:401-407.
44. Schmidt D., Elger C.E. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs?. Epilepsy Behav. 2004, 5:627-635.
45. Schwarz J.R., Grigat G. Phenytoin and carbamazepine: potential- and frequency-dependent block of Na currents in mammalian myelinated nerve fibers. Epilepsia 1989, 30:286-294.
46. Shorvon S.D. Handbook of Epilepsy Treatment 2000, Blackwell, Oxford, UK.
47. 3H]glutamate in hippocampal nerve endings. Neuropharmacology 2007, 52:854-862.
48. + channel-mediated release. Neuropharmacology 2007, 53:854-862.
49. Son J.H., Winzer-Serhan U.H. Postnatal expression of α2 nicotinic acetylcholine receptor subunit mRNA in developing cortex and hippocampus. J. Chem. Neuroanat. 2006, 32:179-190.
50. Stefani A., Pisani A., De Murtas M., Mercuri B., Marciani M.G., Calabresi P. Action of GP 47770, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents. Epilepsia 1995, 336:997-1002.
51. Steinlein O.K., Bertrand D. Nicotinic receptor channelopathies and epilepsy. Pfügers Arch. 2010, 40(2):495-503.
52. Tecoma E.S. Oxcarbazepine. Epilepsia 1999, 40:S37-S49.
53. Wada E., Wada K., Boulter J., Deneris E., Heinemann S., Patrick J., Swanson L.W. Distribution of alpha2, alpha3, alpha4, and beta2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat. J. Comp. Neurol. 1989, 284:314-335.
54. Wessler I., Kirkpatrick C.J. Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. Br. J. Pharmacol. 2008, 154:1558-1571.
55. Whiteaker P., Wilking J.A., Brown R.W.B., Brennan R.J., Collins A.C., Lindstrom J.M., Boulter J. Pharmacological and immunochemical characterization of alpha2*nicotinic acetylcholine receptors (nAChRs) in mouse brain. Acta Pharmacol. Sin. 2009, 30:795-804.
56. Willow M., Gonoi T., Catterall W.A. Voltage clamp analysis of the inhibitory actions of diphenylhydantoin and carbamazepine on voltage-sensitive sodium channels in neuroblastoma cells. Mol. Pharmacol. 1985, 27:549-558.
57. A activation and aggravates absence seizures. Epilepsia 2009, 50:83-87.
58. Zolles G., Wagner E., Lampert A., Sutor B. Functional expression of nicotinic acetylcholine receptors in rat neocortical layer 5 pyramidal cells. Cereb. Cortex 2009, 19:1079-1091.